Sign up Australia
Proactive Investors - Run By Investors For Investors

Actinogen Medical presenting successes with Xanamem at BIO International

Actinogen Medical Ltd (ASX:ACW) CEO and managing director Dr. Bill Ketelbey speaks to Proactive Investors about progress with its promising cortisol inhibitor, Xanamem.

“This is a drug very specifically designed to inhibit cortisol production in the brain, and the essence of that is that persistently raised cortisol has been shown to be associated with the development, and the progression, of Alzheimer’s disease. So our hypothesis is, if you inhibit that cortisol production in the brain you can impact - hopefully improve, hopefully moderate, hopefully stop - the development of Alzheimer’s disease, and that’s where we’re up to now. We are undertaking a large international trial to test that hypothesis,” explains Ketelbey.

The biotech company recently underwent an independent interim analysis of its phase II clinical trial for Xanamem in Alzheimer’s disease, named XanADu, which received the positive recommendation of continuation without modification.

Furthermore, Actinogen Medical recently attracted $17 million in funding from renowned institutional investors including Biotechnology Value Fund, Platinum Investment Management Limited and Australian Ethical Investment. Ketelbey describes it as, “a huge endorsement and validation of the trial, of the business, of the potential, and I guess of the management and science that sits behind it.”

This money will be invested in research into potential new indications for Xanamem. “There is a raft of additional opportunities that present themselves, so in a way Xanamem is a pipeline in a product. Alzheimer’s is the major target that we’re going for, but there’s depression, schizophrenia, Parkinson’s disease, epilepsy, potentially PTSD, post myocardial infarction, a whole raft of additional indications that we’ve been presented with. Probably the most developed and promising one is in diabetes... so as you can see it’s a broad platform of opportunities,” says Ketelbey.

Actinogen Medical will be presenting at BIO International in Boston, USA, next week.

Meet High Peak Royalties Ltd, Yandal Resources, MMJ PhytoTech Ltd, Minotaur Exploration Ltd and Hydroponics Company Ltd at our event, Sydney , 22 October 2018. Register here »
View full ACW profile View Profile

Actinogen Medical Ltd Timeline

December 30 2016

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use